Compounded tirzepatide availability tracker — my results so far

newstart_MO said:

The distinction that resolves most of these threads is between what is true on average and what is true for one person.

There is a second half to this that has not been said yet. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

One concrete data point for the thread. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

Following on from newstart_MO — and this may be the naive question:

What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?

Dr.GutHealth said:

If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way.

This is where I part company with the consensus forming above. Pushing back on the consensus forming here. Consistency is not the same as correctness, and a board that agrees with itself quickly is usually agreeing with the first person who sounded certain.

Correct me if the detail matters more than I have assumed.

Dr.GutHealth said:

If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

That is the short version; the long version is somebody else's post.